GraniteShares YieldBOOST Biotech ETF

Key Statistics

Historical Performance

Total return including reinvested distributions, from adjusted closing prices.

Top Holdings

Top 3 holdings as of Jun 30, 2026 · source: SEC N-PORT. Full holdings & prospectus →

About BIOY

TheFund is an actively managed exchange-traded fund (“ETF”) that seeks (i) to generate cash distributions based on atargeted annual cash distribution level of 12% (the “Annual 12% Target”), and (ii) capital appreciation. The Fund’sstrategy involves: (1) constructing a portfolio of U.S.-listed equity securities of Biotech and Pharma Companies (each, an “UnderlyingSecurity”) (the “Equity Strategy”); and (2) the use of options strategies designed to generate premiums (the“Options Strategies”), which involve using options contracts on Underlying Securities and/or Biotech and Pharma ETFs(described below). Additionally, the Fund will maintain a minor allocation to cash, money market funds or U.S. Treasuries, notexceeding ten percent of its total assets.  EquityStrategy TheAdviser selects Biotech and Pharma Companies (defined below) in which the Fund will invest. To enable the Fund to effectivelyimplement its Options Strategies, the Adviser evaluates the liquidity of a potential company’s common stock and the liquidityof its options contracts. The Fund is generally unconstrained, meaning it may invest in companies of any market capitalizationsize. The Adviser will also evaluate price level and implied volatility (i.e., a measure of how much the market believes the priceof a stock or other underlying asset will move in the future) when selecting companies for investment and will monitor for thesefactors when determining whether to select new companies or remove existing companies from the portfolio. Biotechand Pharma Companies may include companies from foreign countries, including emerging markets. The Underlying Securities may includesuch companies’ U.S.-listed depositary receipts, such as American Depositary Receipts (“ADRs”) and Global DepositaryReceipts (“GDRs”). The Fund will be concentrated in the same industry or industries as those of the Biotech and PharmaCompanies, which subjects the Fund to specific industry-related risks. TheFund’s portfolio will generally be comprised of between fifteen and thirty companies. Dividends, if any, paid by the Fund’sportfolio holdings will contribute to the Fund’s income generation. TheFund will, under normal circumstances, invest in Underlying Securities directly. However, from time to time, the Fund may investin Underlying Securities “synthetically” for tactical reasons or to comply with regulatory requirements. To investsynthetically, the Fund will use options contracts on Underlying Securities (considered indirect or synthetic long holdings ofthe Underlying Securities) to gain exposure to the share price performance of the Underlying Securities. OptionsStrategies – Seeking Premiums Separately,the Fund employs various options strategies focused on generating premiums. Generally speaking, the Fund sells (writes) optionson some or all of the Underlying Securities (and/or Biotech and Pharma ETFs), receiving premiums from counterparties that payfor the right to buy or sell at a set price. These premiums are an important driver of the Fund’s distributions. On a monthlybasis, the Adviser uses one or more options strategies to seek to generate net premiums (i.e., option premiums received, lessoption premiums paid) with a target of approximately 1% per month. Actual results may vary and are not guaranteed. Receiptof an option premium does not always represent income; depending on the outcome of the overall options transaction. Premiumlevels are influenced by market conditions, particularly volatility, and the Adviser may adjust the Fund’s options strategiesdepending on the outlook for the Underlying Securities. While option selling may provide premium opportunities, it may also limitupside gains or increase downside risk. Further, depending on the Adviser’s assessment of one or more of the UnderlyingSecurities’ options contracts (e.g., they are insufficiently liquid or too costly), the Fund may employ Options Strategiesusing a “Biotech and Pharma ETF” (i.e., a passively-managed, U.S.-listed ETF that seeks to track the performance ofan index primarily comprised of Biotech and Pharma Companies). The  Fund applies its options strategies consistently, whichfor Underlying Securities includes whether they are held directly or through synthetic exposure. Theoptions strategy most frequently utilized by the Fund is called a covered call spread, which is a type of selling credit spread.The Fund uses covered call spreads to earn premium by selling a call option while buying another at a higher strike, with bothprofit and loss capped. See the prospectus section titled “Additional Information About the Funds” for a list of theoptions strategies that the Fund may utilize, together with a description of each options strategy. Annual12% Target Distribution Asdiscussed above, the Fund’s options strategies are designed to seek net premiums of approximately 1% per month. The Fundhas also established a target annual cash distribution level of approximately 12% of its net asset value (the “Annual 12%Target”). This target reflects the Adviser’s expectations based on the premiums the Fund seeks to generate and theannualized effect of those premiums. In practice, the Fund’s options strategies are designed to seek monthly distributionlevels of roughly 1%, which, when annualized, correspond to the Annual 12% Target. The Annual 12% Target is not a guarantee,nor does it represent a 12% yield or a 12% total return. Actual distributions may be higher or lower depending on market conditionsand the Fund’s results.  Tothe extent the Fund’s returns fall short of the Annual 12% Target, distributions will reduce the Fund’s net assetvalue (NAV). Although stated as an annual target, distributions are paid more frequently, and any amount the Fund pays in excessof its earnings will reduce NAV. If the Fund’s NAV declines over time, the dollar amount of future distributions will alsodecrease. Distributions may include a significant portion classified as return of capital (“ROC”). ROC generally representsa return of a shareholder’s invested capital rather than traditional income such as dividends or interest. See the prospectussection titled “Additional Information About the Funds” for more information about option premiums and ROC. TheFund seeks to pay distributions on a monthly or more frequent basis, but there is no assurance the Fund will achieve the Annual12% Target in any year. Treasuries Inaddition, the Fund will hold cash or short-term U.S. Treasury securities. These securities serve a dual purpose: providing collateralfor the Options Strategies and contributing to the Fund’s income generation. FundAttributes TheFund is classified as “non-diversified” under the 1940 Act. The Fund’s investment strategy is expected to resultin high portfolio turnover on an annual basis. Undernormal circumstances, the Fund will invest at least 80% of the value of its assets, plus borrowings for investment purposes, inthe equity securities of Biotech and Pharma Companies and options contracts on (i) Biotech and Pharma Companies, and/or (ii) Biotechand Pharma ETFs. For purposes of the foregoing, the Fund defines a “Biotech and Pharma Company” as a company thatgenerates at least 50% of its revenue from the research, development, manufacturing, and commercialization of biotechnologicaland pharmaceutical products, and a “Biotech and Pharma ETF” as a passively-managed, U.S.-listed ETF that seeks totrack the performance of an index primarily comprised of Biotech and Pharma Companies. Thereis no guarantee that the Fund’s investment strategy will be properly implemented, and an investor may lose some or all ofits investment.  

BIOY News

• No recent news found for BIOY.